ClinicalTrials.gg
Active, not recruitingNCT05238883Updated Nov 21, 2025

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

A Phase 1 interventional study of HFB200301 and Tislelizumab in Gastric Cancer, Renal Cell Carcinoma and Melanoma, sponsored by HiFiBiO Therapeutics. Active, not recruiting at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by HiFiBiO Therapeutics · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 805 studies in Stomach Neoplasms with a site in United States — 157 open to participants now, 239 under way, 12 of them phase 3. Stomach Neoplasms · United States.

Enrollment
283rd of 687
72 · median 53
Started
2022
with 54 others
Phase 1
270 of 805
50 open now
Primary completion
2026-12
later than 51 of 238 live
Registered
611th of 805
by date

Among the 805 studies in Stomach Neoplasms with a site in United States, this one is the 283rd largest by enrollment of the 687 interventional ones that give a count, is one of 55 that started in 2022, is one of 270 in phase 1, reaches primary completion later than 51 of the 238 other live ones, and was the 611th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

157 of the 805 studies in Stomach Neoplasms with a site in United States are open now. Recruiting first, the newest first:

152 more — sign in →

All 157 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 805 studies in Stomach Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200301 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200301 as a single agent or combination therapy is determined. During the expansion part, participants will take the dose of HFB200301 as a monotherapy or in combination with tislelizumab that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer the participants have.

Read the detailed description

This is a Phase 1a/1b, first in human, open-label, dose escalation and expansion study in adults with advanced cancers. The study will comprise of

  1. A Screening Period
  2. A Treatment Period during which participants will receive the study drug on the first day of each cycle
  3. A Follow-up Period
03

Conditions studied

  • Gastric Cancer
  • Renal Cell Carcinoma
  • Melanoma
  • Sarcoma
  • Testicular Germ Cell Tumor
  • Cervical Cancer
  • Mesothelioma
  • Non Small Cell Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously received the following for the advanced/ disease:

    • Gastric cancer: at least 2 lines of therapy
    • Renal cell carcinoma: at least 2 lines of therapy
    • Melanoma:

      • BRAF V600E mutant: must have received at least 2 lines of therapy
      • BRAF V600E wild type: must have received at least 1 line of therapy
    • Sarcoma: at least 1 line of therapy
    • Testicular germ cell tumor: at least 2 lines of therapy
    • Cervical cancer: at least 2 lines of therapy
    • Mesothelioma: at least 2 lines of therapy
    • Non-small cell lung cancer: at least 2 lines of therapy
    • Head and neck squamous cell carcinoma: at least 2 lines of therapy
  • Suitable site to at pre-treatment and on-treatment
  • as determined by (RECIST) 1.1 or modified RECIST () for mesothelioma
  • performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Systemic anti-cancer therapy within 2 weeks prior to start of study drug or within 4 weeks for immune-oncologic therapy
  • For soft tissue sarcoma and testicular germ cell tumor patients only: prior immune therapy
  • Therapeutic radiation therapy within the past 2 weeks
  • Prior exposure to agents targeting the Tumor Necrosis Factor Receptor type 2 (TNFR2) receptor
  • Active disease requiring systemic treatment in the previous 2 years
  • Systemic therapy (>10 mg/day of prednisone or equivalent) or any immune suppressive therapy ≤ 14 days before first dose
  • Persisting toxicity of ≥Grade 2 (≥Grade 1 for diarrhea) relating to prior anti cancer therapy with the following exceptions:

    • All grades of alopecia are acceptable
    • Endocrine dysfunction on replacement therapy is acceptable
  • Severe or unstable medical condition, including uncontrolled diabetes, coagulopathy, or unstable psychiatric condition
  • Major surgery within 4 weeks of the first dose of study drug
  • History or presence of drug or non-drug induced interstitial lung disease or pneumonitis ≥Grade 2. For combination only: non-small cell lung cancer patients, mesothelioma or patients with significantly impaired pulmonary function or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening
  • History of allergic reactions, immune related reactions, or cytokine release syndrome (CRS) attributed to compounds of similar chemical or biologic composition to monoclonal antibodies or any of HFB200301
  • Using sensitive substrates of major cytochrome P450 (CYP450) enzymes
  • Known active , with the exception of the specific cancer under investigation in this trial, that required treatment within the previous 2 years
  • For combination only:

    • Prior randomization in a tislelizumab study regardless of the treatment arm, until the primary and key secondary endpoints of the study have read out
    • to tislelizumab or any of its excipients.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Dose Escalation - HFB200301 monotherapy

    Participants will be administered HFB200301 at dose levels 1-5 as an intravenous infusion to determine the Recommended Dose for Expansion (RDE).

    Drug: HFB200301

  • Experimental
    Dose Escalation - HFB200301 in combination with tislelizumab

    Participants will be administered HFB200301 at dose levels 1-4 in combination with one dose level of tislelizumab as an intravenous infusion to determine the combination Recommended Dose for Expansion (RDE).

    Drug: HFB200301 · Drug: Tislelizumab

  • Experimental
    Dose Expansion - HFB200301 monotherapy

    Participants will be administered HFB200301 at monotherapy RDE as an intravenous infusion.

    Drug: HFB200301

  • Experimental
    Dose Expansion - HFB200301 in combination with tislelizumab

    Participations will be administered HFB200301 in combination with tislelizumab at combination RDE as an intravenous infusion.

    Drug: HFB200301 · Drug: Tislelizumab

Interventions

  • DrugHFB200301

    Participants will be administered HFB200301 as described in the experimental arm.

  • Participants will be administered tislelizumab as described in the experimental arm.

    Also known as: BGB-A317

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs), serious AEs (SAEs), dose-limiting toxicities (DLTs), and tolerability (dose interruptions, reductions, and dose intensity)

    Time frame: assessed up to 3 years

  2. To determine a Recommended Phase 2 Dose (RP2D) during Dose Expansion

    Time frame: assessed up to 3 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: assessed up to 3 years

  2. Disease Control Rate (DCR)

    Time frame: assessed up to 3 years

  3. Duration of Response (DOR)

    Time frame: assessed up to 3 years

  4. Progression Free Survival (PFS)

    Time frame: assessed up to 3 years

  5. Maximum serum concentration (Cmax)

    Time frame: average of 3 years

  6. Terminal half-life (T1/2)

    Time frame: average of 3 years

  7. Area under the concentration versus time curve (AUC)

    Time frame: average of 3 years

  8. Serum concentration for measurement of anti-HFB200301 antibodies

    Time frame: average of 3 years

  9. To assess the pharmacodynamic (PD) effects of HFB200301 as a single agent and in combination

    Percent change in immunologic changes to immune cells

    Time frame: average of 3 years

07

Study locations

10 sites
08

References and documents

Publications

  • Gao Z, Zhang Q, Chen H, Chen J, Kang J, Yu H, Song Y, Zhang X. TNFR2 promotes pancreatic cancer proliferation, migration, and invasion via the NF-kappaB signaling pathway. Aging (Albany NY). 2023 Aug 16;15(16):8013-8025. doi: 10.18632/aging.204941. Epub 2023 Aug 16. PubMed 37589506 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.

Of 167 industry-sponsored phase 1 interventional studies under Stomach Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 65. This study's planned 57 months is above that.

Counting every sponsor, half of 242 studies reached it within 51 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2021
First posted
Feb 14, 2022
StartActual
Mar 10, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05238883
Lead sponsor
HiFiBiO Therapeutics
Responsible party
Sponsor
First posted
Feb 14, 2022
Start date
Mar 10, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 21, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion